Chief Executive Officer
Rich Casey joined Neuraltus in September of 2013 as President and CEO, bringing more than 40 years of pharmaceutical and biotechnology industry experience to the organization. Most recently, Mr. Casey was Chairman and CEO of Scios, a biotechnology company working in the areas of cardiovascular disease, inflammation, and Alzheimer’s disease. While at Scios, the company successfully developed Natrecor, a leading treatment for acute congestive heart failure in the United States. The company was sold to Johnson & Johnson in 2003 for $2.4 billion. Prior to Scios, Mr. Casey held a variety of marketing, sales and general management positions with Eli Lilly, Syntex and Alza. He holds a BS in Chemistry and an MBA from Stanford University.
President and Chief Operating Officer
John Whelan joined Neuraltus in 2014 as Chief Operating Officer and Chief Financial Officer, bringing over 25 years of experience to the company. Most recently, Mr. Whelan held the role of President, Chief Executive Officer and Director at A.P. Pharma, a specialty pharmaceuticals company. Prior to his tenure with A.P. Pharma, John held executive leadership positions with several life science companies, including Chief Operating Officer and Chief Financial Officer at Raven Biotechnologies, Inc. and Vice President and Chief Financial Officer at Eos Biotechnology, Inc. Mr. Whelan also held ascending management positions at Hewlett Packard Company, culminating in his tenure as Director of Corporate Development. He holds a BS in Electrical Engineering from University of California, Berkeley and an MBA from the Anderson Graduate School of Management at UCLA.
Michael McGrath, M.D., Ph.D.
Chief Scientific Officer
Dr. Michael McGrath is the company’s Chief Scientific Officer. He is also a Professor of Laboratory Medicine at the University of California, San Francisco (UCSF). Dr. McGrath founded Neuraltus in 2004 based on a broad technology portfolio and intellectual property assembled with the company’s other founding clinical researchers. He has authored over 100 scientific articles with a focus on the role of macrophages in the pathogenesis of chronic neurologic diseases and AIDS. Since joining the staff at UCSF in 1985, Dr. McGrath has held numerous positions including Associate Professor of Laboratory Medicine and Associate Professor of Pathology. Dr. McGrath holds an M.D. and a Ph.D. in Cancer Biology from Stanford University School of Medicine.
Gil Block, M.D., Ph.D.
Chief Medical Officer
Dr. Gil Block joined Neuraltus in 2009 and serves as Acting Chief Medical Officer. Dr. Block is also an Adjunct Professor of Pharmacology & Physiology at Drexel University College of Medicine, where he teaches early stage drug development and translational medicine and neuroscience. He is a member of the external review boards for the NIH Therapeutics for Rare and Neglected Disease (TRND) and the NIH Bridging Interventional Development Gaps (BRIDGS) groups, as well as a consultant for the Gladstone Institutes. In addition, he previously served on the T1 Translational Catalyst Advisory Board of the University of California. Dr. Block was previously Vice President of Clinical Research, Neuroscience and Clinical Pharmacology for Cephalon. Prior to Cephalon, he was Executive Director, Global Medicine and Science for AstraZeneca and Senior Director and Head of Clinical Neuropharmacology for Merck & Co. Dr. Block holds an M.D. and a Ph.D. in Neuropharmacology and Neuroendocrinology from Case Western Reserve University School of Medicine.